Recalled ICD Leads Can Be Extracted Safely, Cleveland Clinic Study Shows
This article was originally published in The Gray Sheet
A 10-year retrospective study from the Cleveland Clinic shows that implantable cardioverter defibrillator leads subject to recalls can be extracted with the same safety and efficacy as non-recalled ICD leads. Another study, published in the same issue of Heart Rhythm, found that younger age and female sex are independent predictors of failure for St. Jude’s Riata lead.
You may also be interested in...
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.
St. Jude Medical: Cardiac Rhythm Management Business Has “Turned The Corner”
The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.
St. Jude Tries To Get Ahead Of Questions On Durata ICD Leads
The company hopes an independent analysis of its Optim-insulated Durata leads will address questions from the clinical community based on concerns with its earlier-generation Riata devices.